HORSHAM, Pa.--(BUSINESS WIRE)--Acurian Inc., the leading full-service provider of global patient enrollment and retention solutions and a subsidiary of Pharmaceutical Product Development, LLC (PPD), has launched a new consulting offering to aid pharmaceutical sponsors in advance strategic planning for clinical trials enrollment. Acurian Consulting Services provides patient-centric, data-driven insights that help drive protocol design, patient enrollment feasibility, site and country planning, CRO selection and budgeting for central recruitment.
Acurian Consulting Services leverages Acurian’s patient-centric global platform, PatientPulse™, to garner both qualitative and quantitative clinical trial insights from patients. The patient perspective is uniquely highlighted, both retrospectively based on millions of data points, and prospectively through large patient surveys and personalized interviews.
Acurian’s feasibility consultants have access to the company’s 100-million-household database and more than 17 million pre-screened study candidates to project how a sponsor’s protocol and study design will play out in terms of enrollment accrual rates, site performance and patient participation.
“With Acurian Consulting Services, we are encouraging sponsors to think differently,” said Roger Smith, Acurian’s senior vice president and general manager. “By engaging in early strategic consulting, they can gain patient insights to plan later phase trials in a more innovative way. Our patient-first feasibility inverts the traditional site-first planning model and gives sponsors confidence to develop enrollment plans with fewer sites – without sacrificing certainty of speed, budget and quality. A smaller site footprint is more efficient and eliminates the need to over-hire sites.”
Sponsors interested in more information can contact firstname.lastname@example.org.
Acurian, a subsidiary of PPD, is the leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time. Learn more at www.acurian.com.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 19,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
Any statements made in this news release that are not statements of historical fact, including statements about Acurian Consulting Services, are forward-looking statements that involve a number of risks and uncertainties. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “might,” “will,” “forecast” and other similar expressions. The forward-looking statements contained in this news release are subject to and involve risks, uncertainties and assumptions, and therefore you should not place undue reliance on them. Although PPD believes these forward-looking statements are based on reasonable assumptions at the time they are made, many factors are beyond PPD’s ability to control or predict and could affect the outcome of the subject matter of this news release and our actual financial results, and therefore the outcome and results might differ materially from those expressed in the forward-looking statements.
Additional factors that might materially affect the forward-looking statements include, but are not limited to: our ability to recruit, retain and motivate key personnel; the competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; rapid technological changes that make our services less competitive or obsolete; the impacts of political, economic and/or regulatory changes on the health care industry; the fact that our backlog may not accurately predict or convert into service revenue; the termination, delay or change in scope of our contracts; industry, customer or therapeutic concentration; the pricing of and cost management of customer contracts; information and communication systems failures; contractual failures; regulatory and ethical standards failures; our ability to attract investigators and enroll patients in clinical trials; violations of laws governing privacy, conduct of clinical trials and/or other pharmaceutical research; competition between existing and potential customers; management of business restructurings and acquisitions; risk relating to the performance of drug development services and our insurance coverages, if any, for such risks; U.S. or international economic, currency, political and other risks; changes in existing or interpretations of tax laws; factors impacting the value of our goodwill and intangible assets; and other factors.
PPD assumes no obligation and expressly disclaims any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. PPD is not responsible for updating the information contained in this news release beyond the published date, or for changes made to this news release by wire services or internet service providers or any other party.